We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Abbott Expands Global Peripheral Technology Portfolio

By HospiMedica International staff writers
Posted on 21 Jul 2013
Abbott Laboratories (Abbot Park, IL, USA) has agreed to buy Idev Technologies (Webster, TX, USA), expanding device offerings for the treatment of cardiovascular diseases. More...


Idev Technologies is a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons, and cardiologists. The purchase will confer it with possession of the Supera Veritas stent, a self-expanding nitinol stent designed to mimic the body’s natural movement, which is currently available to treat narrowing of the bile duct in cancer patients. Under the terms of the agreement, Abbott will acquire all outstanding equity of IDEV Technologies for USD 310 million net of cash and debt.

The stent’s biomimetic principles help promote blood flow in the treated area while offering strength and flexibility, properties that are particularly important when considering treatment for blockages in the blood vessels in the thigh and knee, where rapid and frequent movement occurs with daily activities such as walking, sitting, and standing. The FDA is also reviewing a premarket approval application (PMA) for use of the Supera Veritas in the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA), the main artery in the thigh that supplies blood to lower extremities.

“The acquisition of Idev Technologies will expand and complement Abbott's existing peripheral technology portfolio of guidewires, balloon dilatation catheters and stents, making it one of the most comprehensive and competitive portfolios in the industry,” said Chuck Foltz, senior vice president of vascular at Abbott. “This technology has the potential to make a significant impact on the treatment of patients who suffer from peripheral artery disease, a growing concern around the world.”
In patients with PAD, fatty deposits accumulate on the inner wall of the artery, causing blockages, which reduce the flow of blood to lower parts of the leg. Patients with PAD can experience leg pain when walking and, if untreated, the disease can progress with severe consequences such as critical limb ischemia and amputation. Close to 27 million people in Europe and North America already suffer from PAD, and increasing prevalence is expected to place further economic burden on the healthcare system, making timely and effective treatment an important consideration.

Related Links:

Abbott Laboratories
Idev Technologies



Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Ultrasound System
FUTUS LE
Critical Care Conversion Kit
Adapter+
Imaging Table
Stille imagiQ2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.